Abstract
Sultamicillin, a new orally active semisynthesized β-lactam antibiotic composed of ABPC and sulbactam, was applied to the treatment of ten patients with respiratory infections.
The drug was administered orally, three tablets daily, divided into three doses, for 7 to 14 days.
The results were as follows; clinical effectiveness was excellent in one case, good in five cases, slightly good in one case, ineffective in two cases, and one case was excluded due to contraindication of the drug (pulmonary tuberculosis).
No side effect was observed. Slight temporary elevation of Al-p value was observed in one case.
